Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
TT-16 by Tessa Therapeutics for Gastric Cancer: Likelihood of Approval
TT-16 is under clinical development by Tessa Therapeutics and currently in Phase I for Gastric Cancer. According to GlobalData, Phase...
Data Insights
TT-16 by Tessa Therapeutics for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval
TT-16 is under clinical development by Tessa Therapeutics and currently in Phase I for Human Epidermal Growth Factor Receptor 2...